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Abstract: BACKGROUND Cilengitide is a selective ￿v￿3 and ￿v￿5 integrin inhibitor. Data from phase
2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in com-
bination with standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly
in tumours with methylated MGMT promoter). We aimed to assess cilengitide combined with temo-
zolomide chemoradiotherapy in patients with newly diagnosed glioblastoma with methylated MGMT
promoter. METHODS In this multicentre, open-label, phase 3 study, we investigated the efficacy of
cilengitide in patients from 146 study sites in 25 countries. Eligible patients (newly diagnosed, histologi-
cally proven supratentorial glioblastoma, methylated MGMT promoter, and age ￿18 years) were stratified
for prognostic Radiation Therapy Oncology Group recursive partitioning analysis class and geographic
region and centrally randomised in a 1:1 ratio with interactive voice response system to receive temo-
zolomide chemoradiotherapy with cilengitide 2000 mg intravenously twice weekly (cilengitide group) or
temozolomide chemoradiotherapy alone (control group). Patients and investigators were unmasked to
treatment allocation. Maintenance temozolomide was given for up to six cycles, and cilengitide was given
for up to 18 months or until disease progression or unacceptable toxic effects. The primary endpoint
was overall survival. We analysed survival outcomes by intention to treat. This study is registered with
ClinicalTrials.gov, number NCT00689221. FINDINGS Overall, 3471 patients were screened. Of these
patients, 3060 had tumour MGMT status tested; 926 patients had a methylated MGMT promoter, and
545 were randomly assigned to the cilengitide (n=272) or control groups (n=273) between Oct 31, 2008,
and May 12, 2011. Median overall survival was 26•3 months (95% CI 23•8-28•8) in the cilengitide
group and 26•3 months (23•9-34•7) in the control group (hazard ratio 1•02, 95% CI 0•81-1•29,
p=0•86). None of the predefined clinical subgroups showed a benefit from cilengitide. We noted no
overall additional toxic effects with cilengitide treatment. The most commonly reported adverse events
of grade 3 or worse in the safety population were lymphopenia (31 [12%] in the cilengitide group vs
26 [10%] in the control group), thrombocytopenia (28 [11%] vs 46 [18%]), neutropenia (19 [7%] vs 24
[9%]), leucopenia (18 [7%] vs 20 [8%]), and convulsion (14 [5%] vs 15 [6%]). INTERPRETATION The
addition of cilengitide to temozolomide chemoradiotherapy did not improve outcomes; cilengitide will not
be further developed as an anticancer drug. Nevertheless, integrins remain a potential treatment target
for glioblastoma. FUNDING Merck KGaA, Darmstadt, Germany.
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Background: Cilengitide is a selective αvβ3 and αvβ5 integrin inhibitor. Phase 2 trial data suggested 
antitumour activity of cilengitide as a single agent in recurrent glioblastoma and in combination with 
standard temozolomide (TMZ) chemoradiotherapy (TMZ/RTTMZ) in newly diagnosed 
glioblastoma, particularly in tumours with methylated MGMT promoter.  
Methods: This multicentre, open-label, phase 3 study (NCT00689221) investigated the efficacy of 
cilengitide in patients with newly diagnosed, histologically proven supratentorial glioblastoma with 
methylated MGMT status. After stratification for prognostic Radiation Therapy Oncology Group 
recursive partitioning analysis class and geographic region, patients were centrally randomised 1:1 to 
receive TMZ/RTTMZ with cilengitide 2000 mg i.v. twice-weekly (cilengitide arm) or TMZ/RTTMZ 
alone (control arm). Maintenance TMZ was given for up to 6 cycles, cilengitide was administered for 
up to 18 months, or until disease progression or unacceptable toxicity. The primary endpoint was 
overall survival. Secondary endpoints included progression-free survival (PFS), and safety. Outcome 
was analysed on intent-to-treat basis. 
Findings: Overall, 3471 patients were screened. Of these, 3060 had tumour MGMT status tested; 926 
patients had a methylated MGMT promoter, of which 545 patients (median age, 58 years) were 
randomised to cilengitide (n=272) or control arm (n=273). Median survival was 26·3 months in both 
arms (HR, 1·02; 95% CI, 0·81–1·29; p=0·86). PFS assessed by the Independent Review Committee was 
10·6 months in the cilengitide arm and 7·9 months in the control arm (HR, 0·92; 95% CI, 0·75–1·12; 
p=0·41). Investigator assessed PFS was 13·5 months in the cilengitide arm and 10·7 months in the 
control arm (HR, 0·93; 95% CI, 0·76–1·13; p=0·46). None of the predefined clinical subgroups showed 
a benefit from cilengitide. Treatment was generally well tolerated, no added toxicity was observed 
with cilengitide. Most commonly reported (>5%) grade ≥3 adverse events in the cilengitide and 
control arm, respectively, included lymphopaenia (n=31 vs n=26), thrombocytopaenia (n=28 vs 
n=46); neutropaenia (n=19 vs n=24), leukopaenia (n=18 vs n= 20), and convulsion (n=14 vs n=15).   
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Interpretation: The addition of cilengitide to standard TMZ/RTTMZ did not improve outcome and 
cilengitide will not be further developed as an anticancer agent. Nevertheless, integrins remain a 
potential treatment target for glioblastoma.  
 




Glioblastoma is the most common histological subtype of primary malignant brain tumours, with an 
annual incidence of approximately 3/100,000.1 Glioblastomas are also the most aggressive form of 
primary brain tumours, with a dismal median survival <12 months in population-based studies, and 
median survival of 15–17 months in clinical trials.2–4 The current standard treatment for patients with 
newly diagnosed glioblastoma consists of surgery followed by radiotherapy with concomitant and 
adjuvant temozolomide (TMZ/RTTMZ).2,5Other chemotherapy agents demonstrated little activity 
due to inherent resistance of glioblastoma cells against most cytotoxic agents, or the inability of the 
agents to cross an intact blood-brain barrier and reach their target.6,7  
The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) is an important 
prognostic factor in glioblastoma; its presence has been associated with inferior survival and 
resistance to alkylating chemotherapy.8 Epigenetic silencing of the MGMT gene by promoter 
methylation may lead to it subsequently being unable to protect tumours from cytotoxic damage 
induced by TMZ and thus predict benefit from TMZ chemotherapy.9 In a pivotal randomised trial 
investigating the value of TMZ added to RT in patients with glioblastoma, median survival in patients 
with methylated MGMT promoter was increased from 15·3 months with RT alone to 21·7 months 
with RT and TMZ. 10 However, patients with unmethylated MGMT promoter in the tumour showed 
only a marginal benefit from RT and TMZ treatment, with a median survival of 12·7 vs 11·8 months.  
Although glioblastomas very rarely metastasise, local recurrence at the edge of resection but also at 
distant locations within the brain is frequent. Glioblastoma cells are characterised by high motility 
and invasiveness, requiring complex cell-matrix interactions.11 Integrins are a family of cell-cell and 
cell-extracellular matrix adhesion molecules, involved in a variety of cellular processes, such as cell 
survival, proliferation, migration, invasion, and angiogenesis, and thus can support tumour 
development.12 In particular αvβ3 and αvβ5 integrins are considered key mediators of crosstalk 
between tumour cells and the brain microenvironment in glioblastoma and are overexpressed on 
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tumour cells and vasculature.13–15 Therefore, targeting integrins and the tumour microenvironment is 
considered a promising therapeutic strategy in glioblastoma.15,16 
Cilengitide is a selective inhibitor of αvβ3 and αvβ5 integrins.17 In phase 1/2 studies in patients with 
recurrent or newly diagnosed glioblastoma, cilengitide alone or in combination with TMZ/RTTMZ 
was well tolerated and showed potential antitumour activity.18–22 In a multicentre phase 1/2 study of 
cilengitide added to standard TMZ/RTTMZ in patients with newly diagnosed glioblastoma, survival 
analyses indicated improved outcome compared with historical controls in patients with methylated 
MGMT gene promoter in the tumour, suggestive of synergy between cilengitide and TMZ 
chemotherapy in chemosensitive tumours.20 Patients with and without MGMT promoter methylation 
had median progression-free survival (PFS) of 13·4 and 3·4 months, and a median overall survival of 
23·2 and 13·1 months, respectively.20 Furthermore, two randomised phase 2 studies demonstrated 
improved survival for glioblastoma patients treated with higher (2000 mg) versus lower (500 mg) 
dose of cilengitide, in both the newly diagnosed and recurrent setting.19,21 Preclinical models also 
demonstrated synergistic activity of cilengitide and irradiation.23 Thus, we embarked on the 
randomised phase 3 trial reported here, restricting eligibility to a subgroup of patients with 
glioblastoma with methylated MGMT promoter. The investigation of patients with an unmethylated 





Study design and treatment 
This was a global, multicentre, randomised, controlled, open-label, phase 3 study (NCT00689221). 
Patients were recruited at over 200 study sites in 25 countries worldwide. Prior to randomisation and 
after informed consent, an independent pathology review was performed and MGMT promoter 
methylation status of the tumour was centrally determined by licensed laboratories of MDxHealth 
(Herstal, Belgium) using quantitative methylation-specific polymerase chain reaction (PCR) basically 
as described previously.25 In brief, DNA was isolated from formalin-fixed, paraffin-embedded tumour 
samples using macro-dissected sections; DNA was modified with sodium bisulfite and subjected to 
methylation-specific PCR using ß-actin as a reference gene (ACTB). Patients were considered MGMT 
methylated when the ratio of MGMT to ACTB was 2.0 or more, calculated as (methylated 
MGMT/ACTB)×1000; the cut-off corresponding to the established nadir that separates methylated 
from unmethylated. 26 A minimum of 1250 copies of ACTB were required for a valid result, unless the 
copy number for methylated MGMT was ten or more, which was scored as MGMT methylated. 
Eligible patients were subsequently randomly assigned 1:1 to receive either standard TMZ/RTTMZ 
alone, or with added cilengitide (standard dose of 2000 mg i.v. twice weekly on Days 1 and 4, 
beginning at week 1)3 (Figure 1). RT consisted of 3D conformal RT and was given at 2 Gy per fraction, 
5 days/week, for up to 6 weeks and a total of 60 Gy; TMZ 75 mg/m2 was administered orally 7 
days/week throughout RT, thereafter, starting 4 weeks after the end of RT (week 11) TMZ 150–200 
mg/m2 was administered for 5 consecutive days every 4 weeks for 6 cycles.3 Cilengitide was to be 
continued for up to 18 months or until disease progression (PD) or unacceptable toxicity. In case of 
first occurrence of an unacceptable toxicity considered as study drug-related, cilengitide treatment 
was to be suspended until recovery from the adverse event (AE) to grade ≤2. Thereafter, 
administration could be restarted at the investigator’s discretion at a dose of 500 mg, and gradually 
increased in weekly intervals up to 2000 mg. Cilengitide treatment was to be discontinued 
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permanently if the same severe toxicity recurred. Crossover from the control to the cilengitide arm 
was not allowed. Cilengitide was administered as 1-hour i.v. infusion starting 4 hours before RT; TMZ 
was given orally within 2 hours after completion of cilengitide infusion and at least 1 hour before RT. 
The study was conducted in accordance with the Declaration of Helsinki, the International 
Conference on Harmonisation note for good clinical practice (Topic E6, 1996), and applicable 
regulatory requirements. Study protocol and patient information sheet were approved by the 
Institutional Review Boards or Independent Ethics Committees of the participating institutions and 
competent authorities according to country-specific regulations.  
Randomisation and masking  
Randomisation (1:1) was performed centrally using an interactive voice response system. Patients 
were stratified in blocks according to geographic region (ie, Europe, North America, and Rest of 
World) and Radiation Therapy Oncology Group recursive partitioning analysis class. As this was an 
open-label study, no blinding procedures were applied.  
Key patient eligibility criteria 
Patients aged ≥18 years with newly diagnosed, histologically confirmed supratentorial glioblastoma 
(WHO Grade IV), centrally determined methylated MGMT status, and with an Eastern Cooperative 
Oncology Group performance status (ECOG PS) of 0 or 1 were eligible. Additional inclusion criteria 
were: written informed consent; available tumour tissue from surgery or open biopsy (stereotactic 
biopsy was not allowed) for MGMT promoter methylation status analysis and central pathology 
review; gadolinium-enhanced (Gd) MRI performed within 48 hours postsurgery, or alternatively, Gd-
MRI performed before randomisation; stable or decreasing steroid doses for ≥5 days prior to 
randomisation; and adequate haematological, renal, and liver function. Key exclusion criteria were 
prior chemotherapy within the last 5 years, prior RT of the head (except for low-dose RT for tinea 
capitis), treatment with other investigational agents 30 days before first dose of cilengitide, and prior 
systemic antiangiogenic therapy; history of coagulation disorder associated with bleeding or 
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recurrent thromboembolic events; placement of carmustine wafers (Gliadel®) at surgery; history of 
malignancy within the last 5 years (except curatively treated cervical carcinoma in situ or basal cell 
carcinoma of the skin); clinically manifest cardiovascular insufficiency (NYHA III, IV) or history of 
myocardial infarction during the past 6 months, and uncontrolled arterial hypertension. 
Study endpoints 
The primary endpoint was overall survival. Secondary endpoints included PFS and safety.  
Outcome measures and statistical analyses 
Overall survival was defined as time from randomisation until death; PFS was defined as duration 
from randomisation until first observation of PD or death from any cause. PFS was assessed locally by 
investigators based on Gd-MRI and according to the Macdonald criteria 4 weeks after RT, and 18, 26, 
and 34 weeks after randomisation as well as every 12 weeks thereafter during the follow-up phase. 
In case of suspected pseudoprogression investigators were advised to continue treatment per 
protocol and repeat imaging after 1-2 months. All imaging was reviewed at the end of study 
recruitment by an Independent Review Committee in a blinded manner. For this external review the 
recently (after this study’s protocol initiation) developed and recommended Response Assessment in 
Neuro-Oncology (RANO) rather than the Macdonald criteria were used.27 Overall survival and PFS 
were estimated using the Kaplan-Meier method. Treatment arms were compared using log-rank test 
stratified for randomisation strata. A Cox proportional hazards model with stratification according to 
randomisation strata was used to calculate treatment HR and 95% CIs. No check of proportional 
hazards (PH) assumptions was planned per protocol. Sensitivity analyses were performed unstratified 
and for the per-protocol set. 
AEs were coded according to the Medical Dictionary for Regulatory Activities version 15·0, and their 
severity graded according to National Cancer Institute Common Terminology Criteria for Adverse 
Events version 3·0. All outcome analyses were performed on the intention-to-treat (ITT) population; 
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safety was assessed on patients treated with at least one dose of cilengitide or who were exposed to 
RT or TMZ (safety population).  
The study sample size was based on the assumption of a median overall survival of 23 months for the 
control group, a hazard ratio (HR) for the difference in overall survival between the experimental and 
control arms of 0.71, power of 80%, two-sided significance level of 5%, and accrual of 24 months. 
Based on these assumptions, the target number of events was 266, expected after 21 month follow-
up, and planned sample size was 504 patients or 252 patients per arm. One formal interim analysis 
for futility was planned after observing 25% of planned maximal number of events. All statistical 
analyses were independently performed on mature data with a median follow-up of 29 months 
(interquartile range [IQR], 25–35 months) by both statisticians at Merck KGaA, Darmstadt, Germany, 
and at the European Organisation for Research and Treatment of Cancer (EORTC) using SAS® 
software version 9.1 or later. 
Role of the funding source  
This study was funded by Merck KGaA, Darmstadt, Germany. Study design, data analysis, and data 
interpretation were performed collaboratively by the principal investigators, EORTC, and the Merck 
study team. The Steering Committee oversaw the study. The principal investigators (RS, MW) had full 
access to and reviewed all data, and had final responsibility for the decision to submit for publication. 
Data collection was performed by a clinical research organisation; the database remained blinded to 




Overall, 3471 patients were registered and screened for eligibility; of these, 3060 patients were 
assessed for MGMT methylation status. A total of 926 patients were found to have glioblastoma with 
MGMT gene promoter methylation, including 382 patients who did not to continue to randomisation 
for reasons as depicted in Figure 2. A total of 545 patients were randomised from October 2008 
through May 2011 and constituted the ITT population: 272 patients were scheduled to receive 
cilengitide twice-weekly in addition to standard TMZ/RTTMZ (cilengitide arm) and 273 were to 
receive TMZ/RTTMZ alone (control arm). The median duration from operation or biopsy to 
randomisation was 4·4 weeks (IQR, 3·7−5·4 weeks); the median time from surgery to start of RT was 
6·2 weeks (IQR, 5·3−7·0 weeks) in the cilengitide arm and 5·4 weeks (IQR, 4·6−6·1 weeks) in the 
control arm (cilengitide treatment was to begin one week before RT). Patient baseline and 
demographic characteristics were well balanced across treatment arms; they are summarised in 
Table 1. Overall, 263 patients in the cilengitide arm, and 258 patients in the control arm, received at 
least one dose of study medication (safety population). The main reasons for discontinuing 
treatment in the cilengitide arm were PD (n=157), AE (n=22), and other (n=54), and in the control 
arm, PD (n=153), AE (n=26), and other (n=57). A total of 152 and 151 patients in the cilengitide and 
the control arm, respectively, received a further line of therapy following documented PD 
(Supplementary Table 1).  
Patients in the cilengitide arm (safety population) received cilengitide for a mean (±SD) of 55·6 
(±41·6) weeks, with a mean dose intensity of 3782 (±481) mg/week; 216 patients (82%) received 
≥90% of the planned cilengitide dose. Overall, 237 patients (90%) in the cilengitide arm received 
≥90% of the planned TMZ dose, comparable to 237 patients (92%) in the control group. Furthermore, 
199 and 197 patients (76% and 76%) received ≥90% of the planned dose of RT, in the cilengitide and 
control arms, respectively.  
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Median overall survival was 26·3 months (95% CI, 24–29) in the cilengitide arm and 26·3 months 
(95% CI, 24–35) in the control arm (282 deaths; HR, 1·02; 95% CI, 0·81–1·29; p=0·86; Figure 3A). The 
2-year survival rate did not differ between treatment arms (56% in both; 95% CI, 49%–61% for the 
cilengitide arm, 49%–62% for the control arm). Overall survival was similar in the two treatment 
arms irrespective of stratification according to baseline demographic characteristics and prognostic 
factors (Figure 3B). Median PFS as assessed by the investigator was 13·5 months (95% CI, 10·8–15·9) 
in the cilengitide arm and 10·7 months (95% CI, 8·1–13·3) in the control arm (388 PFS events; HR, 
0·93; 95% CI, 0·76–1·13; p=0·46; Figure 4A). The independent radiological review committee 
determined progression on average one assessment time point earlier in both arms, with a median 
of PFS 10·6 months (95% CI, 8·2–13·4) and 7·9 months (95% CI, 5·9–12·5), respectively, in the 
cilengitide arm and control arm (389 PFS events; HR, 0·92; 95% CI, 0·75–1·12; p=0·41; Figure 4B). 
Additionally, no benefit was observed in overall survival or PFS in the predefined patient subgroups 
with the addition of cilengitide to TMZ/RTTMZ. 
Safety 
Almost all patients experienced some treatment-emergent AEs (TEAEs) (Supplementary Table 2). 
Grade 3 or 4 TEAEs were observed in over half the patients, but there was no difference between the 
treatment arms (169 patients [64%] in the cilengitide arm and 158 [61%] in the control arm). The 
most common TEAEs (any grade and grade ≥3) are summarised in Table 2. Grade 3 or 4 
thromboembolic events occurred more frequently in the cilengitide arm (35 patients [13%]) 
compared with the control arm (23 patients [9%]), but still within the expected range. Grade 3 or 4 
haemorrhages were similar in both arms (4 patients [2%] each per arm). At least one serious AE was 
reported by 138 patients (53%) in the cilengitide arm versus 115 patients (45%) in the control arm. In 
the cilengitide arm, 11 patients (4%) experienced TEAEs leading to death compared with 9 patients 
(3%) in the control arm. Three patient deaths (1%) in each study arm were considered treatment 
related (Supplementary Table 3). In the cilengitide arm, two patients (1%) died of pulmonary 
embolism, and one (<1%) of aspiration pneumonia; none of these patients had myelosuppression. In 
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the control arm, one (<1%) patient died of pancytopaenia and pneumonia, one (<1%) of pneumonia 
after restarting TMZ following pancytopaenia, and one (<1%) of septic shock without 





This large, prospective, phase 3 trial investigating the novel and first-in-class integrin inhibitor 
cilengitide as antitumour therapy in combination with standard chemoradiotherapy failed to 
demonstrate improved outcome. Neither PFS nor overall survival were significantly prolonged, and a 
HR of 1·02 for overall survival suggests absence of any activity. The median overall survival of 26·3 
months observed in both treatment arms is consistent with prior reports and experience in this 
MGMT-methylated glioblastoma patient population who have undergone gross total or partial 
tumour resection. Safety and tolerability of cilengitide in combination with standard treatment were 
confirmed in this large multicentre trial; there was no indication of increased treatment-emergent 
toxicity with the addition of cilengitide. 
These results raise the question of why the antitumour activity of cilengitide observed in prior phase 
2 studies was not seen in this trial. Indeed, the extensive phase 1 and phase 2 clinical development 
programme repeatedly demonstrated objective and durable responses in patients with recurrent 
glioblastoma,18,19 provided evidence for the drug reaching the tumour tissue,22 and indicated a dose-
dependent trend for a potential improved overall survival when comparing a higher and lower 
cilengitide dose in randomised trials for recurrent and newly diagnosed glioblastoma patients.19,21 At 
the same time, cilengitide early development trials used either a lower dose (500 mg) or compared 
different dosing regimens (500 vs 2000 mg cilengitide), but were conducted without standard of care 
controls, and their comparisons were based on historical data,18-21 which is in contrast to CENTRIC, 
where a control arm was included for comparison.  
Cilengitide may induce some normalisation of the blood-brain barrier by itself, thus suggesting 
treatment response on imaging. Considering the short serum half-life of cilengitide of about 2–4 
hours,18–20,28 a schedule of continuous i.v. administration rather than a twice-weekly bolus may have 
been more appropriate. Although low concentrations of cilengitide have been linked to 
proangiogenic activity in experimental tumour models and altered αvβ3 integrin and vascular 
15 
 
endothelial growth factor receptor-2 trafficking,29 we have previously argued that these 
experimental conditions probably do not reflect the clinical scenario of administering 2000 
mg/m2 cilengitide.30 This would be consistent with the observation that the cilengitide arm was 
comparable to the control arms in terms of safety, and no detrimental effect was observed in any 
subgroup analysed in the CENTRIC trial. Functional imaging demonstrating successful tumour 
targeting may also have been helpful.31  
Numerous other agents were explored over the last decade in order to improve outcome of 
glioblastoma patients. Inhibition of angiogenesis remains a prime treatment target. Similarly to 
cilengitide, randomised trials of bevacizumab added to standard TMZ/RT in newly diagnosed 
glioblastoma failed to prolong overall survival, although PFS was prolonged.32,33 These repeatedly 
failed efforts underscore the complexity of this tumour type, and warrant better preclinical models 
and investigation of combined target inhibition and improved collaboration. More extensive and 
ideally controlled early phase clinical trials are needed, and a critical appraisal of the results required 
before moving into definitive large-scale phase 3 evaluations. Despite the negative outcome of the 
here reported trial, targeting integrins remains a theoretically attractive target, as they are involved 
in essential aspects of malignancy such as angiogenesis, migration, and invasion and their patterns in 
malignancies differ from those of their parent tissues, potentially allowing selective targeting.16 
In the CENTRIC trial almost 3500 patients with a rare disease1 were screened and molecularly 
assessed for eligibility over a 2-year period. This underscores the urgent need for novel and better 
treatments for patients suffering from glioblastoma, and shows a substantial number of patients are 
affected by a disease often excluded from clinical drug development programmes. Potentially 
detrimental treatment delays have been a concern when seeking to molecularly characterise tumour 
types before allocation to specific treatments. In our trial the median time to treatment start was 5–
6 weeks, well within the accepted range of up to 7 weeks.2 Similarly, the recently reported AVAglio 
study indicated that 96% of all patients started treatment within 4–7 weeks32 and in a trial evaluating 
treatments for elderly patients the median time to start of RT was 40–46 days.26 Other publications 
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do not report the time interval between surgery and treatment start.33 In our trial there was no 
indication that the time interval between initial diagnosis and treatment start influenced outcome.  
A notable aspect of this trial was the unique collaboration of industry and academia. The trial was 
designed by academic teams of the EORTC and the Canadian Brain Tumor Consortium, in close 
collaboration with the manufacturer of cilengitide, Merck KGaA, Darmstadt, Germany. As this trial 
was designed as a registration trial of an entirely novel compound and a companion diagnostic, study 
sponsorship and management was coordinated by Merck KGaA, but investigators and 
representatives of the EORTC held the majority positions in the Steering Committee and were 
intimately involved in the study conduct and data interpretation. Data of all randomised patients 
were reviewed by the principal investigators, and statistical analyses were performed independently 
by the study teams at Merck and EORTC. Moreover, this close collaboration now allows assured long-
term follow-up and expanded analyses of molecular tumour characteristics by EORTC-based 
platforms. While Merck KGaA is not pursuing further development of this compound, it continues to 
support the collaboration.  
This trial demonstrated the feasibility of performing upfront central histological review and 
molecular testing with no significant delay in an international multicentre setting. This is a 
prerequisite for further drug development towards personalised medicine.  
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Panel: Research in context 
Systematic review 
We screened PubMed and abstracts presented at clinical oncology meetings for reports of clinical 
trials investigating novel agents for newly diagnosed glioblastoma. Apart from combined 
chemoradiotherapy, the current standard treatment of care, the review revealed that there are no 
established alternative treatment options available for these patients, although several targeted 
agents and angiogenesis inhibitors are being investigated. Cilengitide showed activity in early phase 
trials, and efficacy was believed best when combined with other active treatments. Patients with a 
methylated MGMT promoter were found to have a better outcome with current treatments, thus 
this trial molecularly preselected patients with MGMT methylation status. In a joint development by 
academia led by EORTC and the manufacturer this randomised comparative phase 3 trial was 
designed and conducted  
 
Interpretation 
Despite the encouraging results from preclinical and prior phase 1 and 2 studies, the results from this 
randomised phase 3 trial failed to demonstrate any improvement in outcome of glioblastoma 
patients when cilengitide is added to the standard chemoradiotherapy. The failure of cilengitide to 
improve outcomes in newly diagnosed glioblastoma highlights the pitfalls of conducting phase 3 
trials based on limited phase 2 data and represents a drawback for integrin inhibition as a novel 
approach to cancer therapy. Only little progress in the treatment of glioblastoma has been made 
over the last decade. 
The impressive international participation in the screening of over 3000 patients in this trial 
underscores the need for better treatments. We demonstrated that upfront molecular analyses and 
patient population enrichment is feasible. Successful collaboration between academia and industry 
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performing a large clinical trial jointly while allowing for independence of the partners, separate 




The authors would like to thank patients for their trust and participation, and their family members 
for the provided support and care. The authors are grateful to the many dedicated investigators, 
nurses, data-managers and other collaborators at the participating sites. They want to thank Robert 
Janzer (deceased) who also performed the central pathology review. Furthermore, the authors want 
to thank the members of the independent data monitoring committee, Prof Jan C. Buckner, Prof 
Jean-Pierre Armand, Prof Sally Stenning, Prof Sebastian Harder, and Dr Werner Holtbrügge. Finally, 
the authors would like to acknowledge the excellent collaboration of the teams at Merck KGaA, 
Quintiles, MDxHealth, the Canadian Brain Tumor Consortium, and the EORTC.  
Editorial and medical writing assistance was provided by Anna Hooijkaas, PhD, TRM Oncology, The 
Hague, The Netherlands, funded by Merck KGaA, Darmstadt, Germany.  
 
Individual contribution of each author  
RS*: Study oversight, study design, data collection, data review and interpretation, manuscript 
writing 
MEH*: Oversight molecular testing, study design, data collection, data review and interpretation, 
manuscript writing 
TG*: Study design, data collection, data analysis, data interpretation, manuscript writing 
SE*: Radiation therapy oversight, study design, data collection, data interpretation, manuscript 
writing 
JP*: Study design, data collection, data interpretation, manuscript writing 
YKH*: Study design, data collection, data interpretation, manuscript writing 
KDA: Pathology review, manuscript writing 
20 
 
BL: Pathology review, manuscript writing 
TP: Pathology review, manuscript writing 
DG: Data collection and interpretation, patient recruitment, manuscript writing 
JPS: Data collection, data interpretation, manuscript writing 
WW*: Data collection, manuscript writing 
RT: Data collection, manuscript writing 
DHN: Data collection, manuscript writing 
PH: Data collection, manuscript writing 
AW: Data collection, manuscript writing 
MJBT: Data collection and interpretation, manuscript writing 
CCS: Data collection, manuscript writing  
NR: Data collection, manuscript writing 
LT: Data collection, manuscript writing 
UH: Data collection, manuscript writing 
TG: Data collection, manuscript writing 
RDK: Data collection, manuscript writing 
KA: Data collection, manuscript writing 
CMcB: Data collection, manuscript writing 
AAB: Data collection, manuscript writing 
JCT: Data collection, manuscript writing 
OS: Data collection, manuscript writing 
21 
 
TW: Data collection, manuscript writing 
CYK: Data collection, manuscript writing 
LBN: Study design, data collection, data interpretation, manuscript writing 
DAR*: Study design, data collection, data interpretation, manuscript writing 
MJvdB*: Study design, data collection, manuscript writing 
CH: Study design, data collection, data analysis, data interpretation, manuscript writing  
AM: Medical and scientific study support, data collection, data interpretation, manuscript writing 
MP*: Study oversight, study design, data collection, data review and interpretation, manuscript 
writing 
MW*: Study oversight, study design, data collection, data review and interpretation, manuscript 
writing 
*Indicates steering committee member. 
 
Conflicts of interest 
RS: expenses in relationship with study from Merck KGaA; advisory board for Roche, MSD/Merck & 
Co; and Novartis. 
MEH: service contract from Merck Serono; grant from MDxHealth; personal fees from MSD; advisory 
fees from Roche and MDxHealth.  
SE: grant from Merck KGaA.  
TP: travel grant, honoraria, and payment for reference pathology from Merck, Roche, and Antisense 
Pharma.  
JPS: advisory board for Roche and Mundipharma; personal fees from Medac; grant for independent 
scientific project from Merck. 
22 
 
WW: grants from Roche, MSD, Eli Lilly, Boehringer Ingelheim, and Apogenix; personal fees from 
Roche and MSD.  
RT: personal fees from Merck KGaA. 
DHN: research funding from Merck Serono, Eli Lilly, Oncosynergy, and Regulus.  
AW: personal fees from Roche.  
MJBT: personal fees from Hoffman La Roche. 
UH: consultancy role for Roche, personal fees from Roche, Medac, Mundipharma, research funding 
from Roche, Medac. 
TG: grant from Merck KGaA.  
KA: personal fees from Quintiles Eastern Holding.  
CMcB: personal fees from Roche. 
JCT: personal fees from Merck Serono, Roche, and Medac; grants from the German Cancer 
Foundation (Krebshilfe), German Research Foundation (DFG), and the German Ministry of Research 
and Technology (BMBF).  
OS: personal fees from Roche. 
DAR: personal fees from Roche/Genentech, Merck/Schering, EMD Serono, Novartis, Amgen, 
Stemline Therapeutics, and Momenta Pharmaceuticals.  
MJvdB: personal fees from Merck KGaA, Hoffman La Roche, AstraZeneca, Abbvie, and MSD; grants 
from Hoffman La Roche and Abbvie. 
CH: employed by Merck KGaA; owner of stock from Merck KGaA. 
AM, MP: employed by Merck KGaA. 
23 
 
MW: consultant or advisory role for Isarna, Merck Serono, Roche, and Magforce; personal fees from 
Merck Serono, Roche, MSD, and Magforce; research funding from Bayer, Merck Serono, Roche, MSD, 
and Isarna. 





1. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and 
central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-Oncol 
2012;14:v1–49. 
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant 
temozolomide for glioblastoma. N Engl J Med 2005;352:987–96. 
3. Johnson DR, O’Neill BP. Glioblastoma survival in the United States before and during the 
temozolomide era. J Neurooncol 2012;107:359–64. 
4. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed 
glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013;31:4085–91 
5. Weller M, Van den Bent M, Hopkins K, et al., for the European Association for Neuro-
Oncology (EANO) Task Force on Malignant Glioma. EANO Guideline on the Diagnosis and 
Treatment of Malignant Glioma. Lancet Oncol 2014; in press. 
6. Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF. Delivery of molecularly targeted 
therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 2011;13:e17. 
7. Haar CP, Hebbar P, Wallace GC 4th, et al. Drug resistance in glioblastoma: a mini review. 
Neurochem Res 2012;37:1192–200. 
8. Jaeckle KA, Eyre HJ, Townsend JJ, et al. Correlation of tumor O6 methylguanine-DNA 
methyltransferase levels with survival of malignant astrocytoma patients treated with bis-
chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998;16:3310–5. 
9. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-
methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients 
treated with temozolomide. Clin Cancer Res 2004;15:1871–4. 
25 
 
10. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide 
in glioblastoma. N Engl J Med 2005;352:997–1003. 
11. Hoelzinger DB, Demuth T, Berens ME. Autocrine factors that sustain glioma invasion and 
paracrine biology in the brain microenvironment. J Natl Cancer Inst 2007;99:1583–93. 
12. Stupack DG. The biology of integrins. Oncology (Williston Park) 2007;21:6–12. 
13. Bello L, Francolini M, Marthyn P, et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression 
in glioma periphery. Neurosurgery 2001;49:380–9. 
14. Schnell O, Krebs B, Wagner E, et al. Expression of integrin alphavbeta3 in gliomas correlates 
with tumor grade and is not restricted to tumor vasculature. Brain Pathol 2008;18:378–86. 
15. Roth P, Silginer M, Goodman SL, et al. Integrin control of the transforming growth factor-β 
pathway in glioblastoma. Brain 2013;136:564–76. 
16. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic 
opportunities. Nat Rev Cancer 2010;10:9–22. 
17. Smith JW. Cilengitide Merck. Curr Opin Investig Drugs 2003;4:741–5.  
18. Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of 
cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007;25:1651–7. 
19. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-
targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin 
Oncol 2008;26:5610–7. 
20. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with 
concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in 
patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28:2712–8. 
26 
 
21. Nabors LB, Mikkelsen T, Hegi ME, et al. A safety run-in and randomized phase 2 study of 
cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). 
Cancer 2012;118:5601–7. 
22. Gilbert MR, Kuhn J, Lamborn KR, et al. Cilengitide in patients with recurrent glioblastoma: the 
results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 
2012;106:147–53. 
23. Mikkelsen T, Brodie C, Finniss S et al. Radiation sensitization of glioblastoma by cilengitide 
has unanticipated schedule-dependency. Int J Cancer 2009;124:2719–27. 
24. Nabors LB, Fink KL, Mikkelsen T, et al. Cilengitide in combination with standard treatment for 
patients with newly diagnosed glioblastoma with unmethylated O6-methylguanine-DNA 
methyltransferase (MGMT) gene promoter: key results of the open-label, controlled, 
randomized phase II CORE study. Neurooncol 2013;15:viii75–84. Abstract MR-021. 
25. Vlassenbroeck I, Califice S, Diserens AC, et al. Validation of real-time methylation-specific PCR 
to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in 
glioma. J Mol Diagn 2008;10:332–7. 
26. Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week 
radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with 
glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012;9:916–26. 
27. Wen YP, Macdonald DR, Reardon DA, et al. Updated Response Assessment Criteria for High-
Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 
2010;28:1963–72.  
28. Hariharan S, Gustafson D, Holden S, et al. Assessment of the biological and pharmacological 
effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide 
(EMD 121974), in patients with advanced solid tumors. Ann Oncol 2007;18:1400–7. 
27 
 
29. Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and angiogenesis by low 
concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009;15:392-400. 
30. Weller M, Reardon D, Nabors B, et al. Will integrin inhibitors have proangiogenic effects in 
the clinic? Nat Med. 2009;15:726; author reply 727. 
31. Schnell O, Krebs B, Carlsen J, et al. Imaging of integrin alpha(v)beta(3) expression in patients 
with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol 
2009;11:861–70. 
32. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly 
diagnosed glioblastoma. N Engl J Med 2014;370:709–22.  
33. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly 







Table 1. Patient baseline characteristics and demographics (ITT population) 
 




Age (years)   
 Median (range) 58 (22–81) 58 (22–79) 
Sex, n (%)   
 Male 148 (54) 143 (52) 
Region, n (%)   
North America 32 (12) 33 (12) 
Europe 185 (68) 183 (67) 
Rest of the World 55 (20) 57 (21) 
ECOG performance status, n (%)   
 0 156 (57) 151 (55) 
 ≥1 116 (43) 121 (44) 
 Missing 0 (0) 1 (<1) 
RPA class, n (%)   
 III 44 (16) 42 (15) 
 IV 184 (68) 171 (63) 
 V 43 (16) 55 (20) 
 Missing 1 (<1) 5 (2) 
MMSE, n (%)    
 <27 45 (17) 61 (22) 
 ≥27 225 (83) 207 (76) 
 Missing 2 (<1) 5 (2) 
Extent of resection, n (%)    
 Gross total resection 132 (49) 137 (50) 
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 Partial resection 131 (48) 127 (47) 
 Biopsy 9 (3) 7 (3) 
 Missing 0 (0) 2 (1) 
Antiepileptics (baseline), n (%)    
 EIAED 54 (20) 57 (21) 
 Non-EIAED only 99 (36) 121 (44) 
 None 119 (44) 94 (34) 
Steroids (baseline), n (%)    
 Yes 103 (38) 113 (41) 
Time from diagnosis to 
randomisation (weeks) 
  
 Median (range) 4·1 (0·3–9·0) 4·0 (1·4–7·4) 
Time from diagnosis to  
start of RT (weeks) 
  
 Median (range) 6·2 (5·3−7·0) 5·4 (4·6−6·1) 
 
ITT, intention-to-treat; ECOG, Eastern Cooperative Oncology Group; RPA, recursive partitioning 






Table 2. Most common TEAEs by preferred term (safety population; any grade observed in at least 
10% of patients or grade ≥3 reported in at least 2% of patients)* 
Preferred term, n (%) 
Cilengitide arm (n=263) Control arm (n=258) 
Any 
grade 
Grade 3 Grade 4 Any 
grade 
Grade 3 Grade 4 
Nausea 130 (49) 3 (1) - 127 (49) 5 (2) - 
Headache 119 (45) 10 (4) - 88 (34) 8 (3) - 
Fatigue 102 (39) 14 (5) - 85 (33) 8 (3) - 
Constipation 102 (39) 2 (1) - 78 (30) - - 
Vomiting 80 (30) 3 (1) - 87 (34) 9 (3) - 
Alopecia 70 (27) 2 (1) - 70 (27) 1 (<1) - 
Thrombocytopaenia 62 (24) 15 (6) 13 (5) 70 (27) 20 (8) 26 (10) 
Convulsion 57 (22) 9 (3) 5 (2) 28 (11) 13 (5) 2 (1) 
Decreased appetite 54 (21) 1 (<1) - 45 (17) - - 
Cough 51 (19) 1 (<1) - 23 (9) - - 
Asthaenia 47 (18) 8 (3) - 21 (8) 3 (1) - 
Lymphopaenia 46 (17) 24 (9) 7 (3) 36 (14) 24 (9) 2 (1) 
Diarrhoea 45 (17) 3 (1) - 20 (8) 2 (1) - 
Dizziness 36 (14) 2 (1) - 25 (10) 1 (<1) - 
Oedema peripheral 36 (14) 2 (1) - 24 (9) 1 (<1) - 
Neutropaenia 35 (13) 10 (4) 9 (3) 29 (11) 11 (4) 13 (5) 
Insomnia 35 (13) - - 24 (9) - - 
Leukopaenia 33 (13) 13 (5) 5 (2) 33 (13) 11 (4) 9 (3) 
Nasopharyngitis 32 (12) - - 11 (4) - - 
Pruritus 32 (12) 2 (1) - 15 (6) - - 
Back pain 31 (12) 1 (<1) - 8 (3) 2 (1) - 
Pyrexia 30 (11) 2 (1) - 19 (7) - - 
Rash 28 (11) 1 (<1) - 19 (7) 1 (<1) - 
Upper respiratory tract 
infection 

















*If a patient experienced more than 1 AE within a preferred term, the patient was counted once in 
the term. 
In this study, grade 5 was not possible to assign to an AE; those AEs were recorded as grade 3 or 4 
leading to death (Supplementary Table 3).  
AE, adverse events; TEAE, treatment-emergent adverse event. 
 
 
Memory impairment 27 (10) 1 (<1) - 18 (7) 1 (<1) - 
Aphasia 25 (10) 6 (2) - 12 (5) 5 (2) - 
Haemiparesis 21 (8) 11 (4) 1 (<1) 11 (4) 4 (2) 1 (<1) 
Alanine 
aminotransferase 
21 (8) 7 (3) - 17 (7) 4 (2) - 
Aneamia 17 (6) 7 (3) - 17 (7) 2 (1) 2 (1) 
Pneumonia 15 (6) 9 (3) 2 (1) 11 (4) 3 (1) 3 (1) 
Peripheral motor 
neuropathy 
14 (5) 9 (3) - 3 (1) 1 (<1) - 
Hyperglycaemia 13 (5) 11 (4) - 8 (3) 5 (2) - 
Deep vein thrombosis 13 (5) 10 (4) - 6 (2) 4 (2) 2 (1) 
Lymphocyte count 
decreased 
13 (5) 7 (3) 3 (1) 6 (2) 1 (<1) 1 (<1) 
Pulmonary embolism 13 (5) 2 (1) 10 (4) 8 (3) 1 (<1) 6 (2) 
Hyponatraemia 14 (5) 4 (2) 2 (1) 8 (3) 7 (3) - 









MGMT, O6-methylguanine-DNA methyltransferase; R, randomisation; i.v., intravenous; TMZ, 




Figure 2. CONSORT statement diagram.  
 
 
*Pre-screening for methylation status of the MGMT gene promoter. 
†Reasons for exclusion as reported by the investigator. 
‡1 patient with unmethylated MGMT gene promoter was randomised erroneously. 
MGMT, O6-methylguanine-DNA methyltransferase; ICF, informed consent form; ITT, intention-to-




Figure 3. Kaplan-Meier plot of OS (A) and forest plot (B) detailing OS based on patient demographics (ITT 
population).  
 
*Stratified HR is displayed in all Kaplan Meier analyses; unstratified HRs are displayed in all subgroup 
analyses. 
HR, hazard ratio; CI, confidence interval; OS, overall survival; TMZ, temozolomide; RT, radiotherapy; 
CIL, cilengitide; MGMT, O6-methylguanine-DNA methyltransferase; NR, median not yet reached; RPA, 
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recursive partitioning analysis; ITT, intention-to-treat; ECOG PS, Eastern Cooperative Oncology Group 




Figure 4. PFS as assessed by the investigator (A) and assessed by the IRC (B) (ITT population).  
 
CIL, cilengitide; CI, confidence interval; HR, hazard ratio; ITT, intention-to-treat; PFS, progression-free 
survival; TMZ, temozolomide; RT, radiotherapy. 
 
Assessed for MGMT promoter  
methylation status (n=3060) 
Methylated MGMT promoter (n=926) 
Excluded† (n=382) 
Eligibility criteria not met (n=157) 
Pathology not confirmed/insufficient tissue quality (n=13) 
Early tumour progression or death (n=35) 
Intercurrent complications (n=10) 
Withdrawal of consent (n=163) 






Supplementary Table 1. Treatment following documented PD (ITT population) 




Patients with documented PD, n (%) 157 (58) 153 (56) 
Treatment following documented PD, n (%)    
 ≥1 Therapy 152 (56) 151 (55) 
 Surgery 32 (12) 25 (9) 
 Radiotherapy 26 (10) 40 (15) 
 Cytotoxic chemotherapy 113 (42) 105 (39) 
 Hormonal 1 (<1) 0 (0) 
 Anti-VEGF (other than bevacizumab) 29 (11) 27 (10) 
 Bevacizumab 52 (19) 54 (20) 
 Other antiangiogenic 24 (9) 25 (9) 
 Other 19 (7) 21 (8) 




Supplementary Table 2. Patients with TEAEs (safety population) 







   Any 
   Study treatment related 










   Any 
   Study treatment related 









NCI-CTCAE grade 3 or 4 TEAEs 
   Any 
   Study treatment related 









TEAEs leading to death 
   Any 
   Study treatment related 









TEAEs leading to permanent discontinuation of 
At least 1 study treatment 
Cilengitide 
 





TEAEs leading to dose reduction of 
At least 1 study treatment 
Cilengitide 
 





*A serious AE, experience, or reaction is any untoward medical occurrence that at any dose results in death or is 
life-threatening (ie, refers to an event in which the patient was at risk of death at the time of the event). 
Study treatment-related: cilengitide, radiotherapy, and/or temozolomide. 
AE, adverse event; NA, not applicable; NCI-CTCAE, National Cancer Institute Common Terminology Criteria 





Supplementary Table 3. Study treatment-related AEs leading to death by SOC/preferred term (safety 
population)* 






Number of patients with ≥1 AE 3 (1) 3 (1) 
Blood and lymphatic system disorders 
   Leukopaenia 













Infections and infestations 
   Pneumonia 
















*If a patient experienced ≥1AE within a SOC/preferred term, the patient was counted once in that SOC/preferred 
term.  
Study treatment-related: cilengitide, radiotherapy, or temozolomide. 
AE, adverse event; SOC, System Organ Class. 
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Appendix – list of participating institutions  
 
Argentina: Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia - FLENI (B. Diez), 
Instituto Médico CER (M.S. Varela), Sanatorio Parque (S. Kahl) 
 
Australia: Haematology & Oncology Clinics of Australia – HOCA (P. Eliadis), Royal Melbourne Hospital (M. 
Rosenthal), Austin Health (L. Cher), The Queen Elizabeth Hospital (K. Patterson), Royal North Shore Hospital 
(H. Wheeler), Calvary Mater Newcastle Hospital (S. Ackland), Royal Brisbane & Women's Hospital (J. Goh), 
Flinders Medical Centre (G. Kichenadasse) 
 
Austria: Universitätsklinik für Innere Medizin I (C. Marosi), Universitätsklinik Graz (F. Payer), St. Johanns 
Spital – Landeskrankenhaus (R. Greil), Universitätsklinik Innsbruck (G. Stockhammer), Kaiser-Franz-Josef 
Spital (W. Grisold)  
 
Belgium: UZ Brussel (B. Neyns), U.Z. Gasthuisberg (P. Clement), ZNA Middelheim (D. Schrijvers), Grand 
Hôpital Charleroi (J.L. Canon), Onze-Lieve-Vrouwziekenhuis (L. Verbeke), ZOL (J. Wuyts), UZ Gent (T. 
Boterberg), Cliniques universitaires UCL de Mont-Godinne (L. D'Hondt) 
 
Brazil: Hospital Sao Lucas – PUCRS (F. Viola), HC da Faculdade de Medicina de Ribeirão Preto da USP (F. 
Maris Peria), IAMSPE (J.M. Rotta), Nucleo de Estudos Oncológicos (M.d. S. Oliveira), Hospital do Cancer - 
Instituto do Cancer do Ceara (M. Gifoni), CEPON (Y.V.N. Nascimento)  
 
Canada: London Health Sciences Centre (D. MacDonald), Windsor Regional Cancer Centre (Y. Alam), 
Montreal Neurological Institute and Hospital McGill University (T. Muanza), Queen Elizabeth II Health 
Sciences Centre (M. MacNeil), Tom Baker Cancer Centre (G. Lim), CancerCare Manitoba (M. Pitz), 
Sunnybrook Health Sciences Centre (J. Perry), Cross Cancer Institute (D. Fulton), Hamilton Health Sciences-
Juravinski Cancer Centre (H. Hirte), CHUS Hopital Fleurimont (D. Mathieu)  
 
Czech Republic: Klinika Onkologie a Radioterapie - Fakultni nemocnice Hradec Kralove (J. Petera), Oddeleni 
radiacni onkologie - Krajska nemocnice Liberec (M. Machanova), Ustav radiacni onkologie 1LF UK - Fakultni 
nemocnice Na Bulovce (V. Stahalova), Radioterapeuticko-Onkologicke oddeleni Fakultni nemocnice v Motole 
(J. Prausova), Klinika radiacni onkologie - Masarykuv onkologicky ustav (P. Slampa), Onkologicke a 
Radoterapeuticke - oddeleni Fakultni nemocnice Plzen (J. Finek)  
 
France: CH Pitié-Salpétrière (J.Y. Delattre), CHU de la Timone (O. Chinot), Centre Val d'Aurelle Paul 
Lamarque (M. Fabbro), Centre René Gauducheau (M. Campone), Institut Gustave Roussy (J. Domont), CHU 
d'Angers (P. Menei), CLCC Paul Strauss (R. Schott), Hopital Neuro Cardiologique (J. Honnorat), CHRU 
Hopital Roger Salengro (F. Dubois), Institut Claudius Regaud (E. Moyal), Centre Antoine Lacassagne (M. 
Frenay), Hopital Pellegrin Tripode (H. Loiseau), Centre Léon Bérard (D. Frappaz), Hôpital Central - Service 
Neurologie (L. Taillandier), Centre Hospitalier de Valenciennes (E. Le Rhun), CHU Carémeau (C. Campello) 
 
Germany: Universitaetsklinikum Dresden (D. Krex), Knappschaftskrankenhaus Bochum-Langendreer (U. 
Schlegel), LMU München - Klinikum Großhadern Neurochirurgische Klinik und Poliklinik (O. Schnell, J.C. 
Tonn), Universitaetsklinikum Freiburg (A. Weyerbrock), Charitè - Universitaetsmedizin Berlin (P. Vajkoczy), 
Universitaetsklinikum Bonn (U. Herrlinger), Klinikum der J.W. Goethe Universitaet Frankfurt (J.P. Steinbach), 
Universitaetsklinikum Heidelberg (W. Wick), Universitaetsklinikum Regensburg (P. Hau), 
Universitaetsklinikum Ulm (T. Wiegel), Sozialstiftung Bamberg (P. Rieckmann), University Wuerzburg (G. 
Vince), Universitaetsklinikum Leipzig (R.D. Kortmann), Klinikum Nuernberg (J. Birkmann), Klinikum rechts 
der Isar TU Muechen (F. Schmidt), Universitaetsklinikum Magdeburg (G. Gademann), Universitaetsklinikum 
Schleswig-Holstein (H.M. Mehdorn), Universitaetsklinikum Goettingen (V. Rohde), Katharinenhospital (N. 
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Hopf), Universitaetsklinikum Hamburg-Eppendorf (O. Heese), Klinikum der Universität Köln (R. Goldbrunner). 
Vivantes-Klinikum Neukoelln (M. de Wit), Universitaetsklinikum Essen (W. Sauerwein)  
 
Hong Kong: Queen Mary Hospital (J. Tsang), Tuen Mun Hospital (C.H. Wong) 
 
Hungary: Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum (J. Szanto), Borsod-Abauj-Zemplen 
Megyei Korhaz es Egyetemi Oktato Korhaz (C. Olah), Szegedi Tudomanyegyetem (L. Thurzo), Kaposi Mor 
Oktato Korhaz (K. Pali)  
 
India: Ruby Hall Clinic Services Pvt. Ltd (A.B. Bhanage), Apollo Speciality Hospital (P. Mahadev), 
Indraprastha Apollo Hospital (G.K. Jadhav), Bangalore Institute of Oncology (N. Rao), ACTREC - Tata 
Memorial Center (T. Gupta)  
 
Israel: Haddasah Ein Kerem M.C (T. Siegal), Rambam Health Care Campus (T. Tzuk), Chaim Sheba Medical 
Center (A. Taliansky), Tel-Aviv Sourasky Medical Center (D. Blumenthal), Rabin M.C (Y. Kundel)  
 
Italy: Ospedale Bellaria (A. Brandes), IRCCS Istituto Nazionale Tumori "Regina Elena" (C. Carapella), Istituto 
Scientifico Ospedale San Raffaele (M. Reni), Fondazione IRCCS (A. Silvani), Ospedali Civili di Brescia (M. 
Scerrati), Istituto Clinico Humanitas (A. Santoro), Policlinico di Modena (P.F. Conte), Azienda Sanitaria 
Ospedaliera S. Giovanni Battista-Le Molinette (R. Soffietti), Ospedali Civili di Brescia (S.M. Magrini), Presidio 
Ospedaliero Marconi Bufalini (M. Faedi), Università degli studi-Policlinico Careggi (G. Biti), IRCCS Ospedale 
Busonera (V. Zagonel)  
 
Netherlands: VU Medisch Centrum (J. Buter), Erasmus MC-Daniel den Hoed (M.J vd Bent), Medisch Centrum 
Haaglanden (M.J.B. Taphoorn), St. Elizabeth Ziekenhuis (L.V. Beerepoot) 
 
Poland: Centrum Onkologii (A. Kawecki), Centrum Onkologii - Instytut Oddział w Gliwicach (R. Tarnawski), 
Akademickie Centrum Kliniczne Szpital AM w Gdansku (J. Jassem), Centrum Onkologii im. Prof. F. 
Lukaszczyka w Bydgoszczy (K. Roszkowski), ZOZ MSWiA (S. Nawrocki), Wojewódzki Szpital 
Specjalistyczny im. M. Kopernika w Łodzi (J. Fijuth), Wielkopolskie Centrum Onkologii (K. Adamska), 
Beskidzkie Centrum Onkologii (D. Imielska-Zdunek), Dolnoslaskie Centrum Onkologii (A. Maciejczyk), 
Specjalistyczny Szpital im. dr A. Sokolowskiego (I. Wlodarska-Polinska), Centrum Onkologii Ziemi Lubelskiej 
(M. Mazurkiewicz)  
 
Serbia: Clinical Hospital Center Zemun (I. Berisavac), Institute for Neurosurgery - Clinical Center Serbia (D. 
Grujicic)  
 
Singapore: National Neuroscience Institute (E. Wang), National University Hospital (N. Chou)  
 
Slovakia: Onkologicky ustav svatej Alzbety (S. Spanik), Fakultna NsP Bratislava - Nemocnica akad. L. Derera 
(P. Kalina), Vychodoslovensky onkologicky ustav a.s (P. Dubinsky), Fakultná nemocnica s poliklinikou F. 
Roosevelta (V. Malec), Narodny onkologicky ustav (I. Koza)  
 
South Korea: Asan Medical Center (J.H. Kim), Catholic University of Korea - Seoul St. Marys Hospital (Y.K. 
Hong), Korea Cancer Center Hospital (C.H. Rhee), Seoul National University Bundang Hospital (C.Y. Kim), 





Spain: Hospital Clinic i Provincial (N. Vinolas), Hospital Universitario La Fe (G. Reynes), Hospital Vall 
d'Hebron (J. Rodon), Hospital Universitario La Paz (C. Belda), Hospital General de Valencia (A. Berrocal), 
Hospital Germans Trias i Pujol (C. Balaña), Hospital Clínico San Carlos Servicio de Oncología Planta Baja (P. 
Perez Segura), ICO-Institut Català d'Oncologia (S. del Barco), HGU de Elche (B. Sánchez) 
 
Switzerland: Centre Hospitalier Universitaire Vaudois (R. Stupp), Inselspital - Universitätsspital Bern (A. 
Ochsenbein), UniversitätsSpital Zürich (M. Weller), Ospedale San Giovanni (G. Pesce), Kantonsspital Aarau (C. 
Mamot), Universitätsspital Basel (K. Conen), Kantonsspital St. Gallen (T. Hundsberger)  
 
Taiwan: National Taiwan University Hospital (Y.K. Tu), Chi Mei Medical Center (C.C. Chio), Taichung 
Veterans General Hospital (C.C. Shen), Taipei Municipal WanFang Hospital (K.S. Hung), Chang-Gung 
Memorial Hospital - Linko (C.N. Chang)  
 
United Kingdom: Clatterbridge Centre for Oncology (B. Haylock), Beatson West of Scotland Cancer Centre 
(A. James), Edinburgh Cancer Centre (S.C. Erridge), The Christie NHS FT (C. McBain), University College 
Hospital London (P. Mulholland), Aberdeen Royal Infirmary (D. Hurman) 
 
USA: Duke University Medical Center (A. Desjardins), H. Lee Moffitt Cancer Center and Research Institute (E. 
Pan), Dartmouth-Hitchcock Medical Center (C. Fadul), University of Florida (E. Dunbar), Barrow Neurological 
Institute (L. Ashby), Baylor University Medical Center (K. Fink), The University of Tennessee (L.M. Michael), 
UC Davis Medical Center (R. Schrot), University of Washington School of Medicine (M. Mrugala), Henry Ford 
Health Systems (T. Mikkelsen), Washington University School of Medicine (K. Rich), Cedars-Sinai Medical 
Center (J. Rudnick), University of Rochester (N. Mohile), Case Medical Center (C. Nock), Columbia University 
Medical Center (R. Lai), Monmouth Medical Center (S. Raval), Wake Forest University Health Sciences (G. 
Lesser), Indiana University School of Medicine (E. Dropcho), Penn State Milton S. Hershey Medical Center (M. 
Glantz), Legacy Clinical Research & Technology Center (J. Chen), St. Francis Medical Group Indianapolis (G. 
Smith), North Shore University Hospital (M. Schulder), St. Lukes Hospital (M. Salacz), Virginia Piper Cancer 
Institute (J. Trusheim), University of Alabama at Birmingham (L. Nabors), Emory University (A. Voloschin), 
The Ohio State University (H. Newton), Vanderbilt University Medical Center (P. Moots), Tisch Hospital Center 
- New York University School of Medicine (D. Gruber), Langone Medical Center (H. Krouwer), University of 
Nebraska Medical Center (P. Bierman), LAC-USC Medical Center (T. Chen), Mount Sinai School of Medicine 
(A. Demopoulos), Rhode Island Hospital (S. Jeyapalan), Tupelo Neurology Clinic (R. Maron)  
 
 
